CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 185 enrolled
Drug / intervention
Engerix™-Bbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01138098
NCT01138098Phase 4Completed
CompareCT.gov

Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in 11-12 Year Old Children, Previously Vaccinated With DTPa-HBV-IPV/Hib Vaccine in Study 217744/031

GlaxoSmithKline·interventional·Posted Jun 7, 2010·Updated Aug 20, 2018

In Brief

A Phase 4 clinical trial evaluating Engerix™-B for Hepatitis B. Completed, enrolled 185 participants across 11 sites.

Detailed Summary

This study will evaluate the persistence of immunity to hepatitis B 10 to 11 years after vaccination with Infanrix hexa™ or Engerix™-B and also the ability to mount an immune response to the challenge dose of Engerix™-B.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B
CountriesSlovakia
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2010
Enrollment StartJun 7, 2010
Primary CompletionNov 26, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.1 years ago

Interventions

Engerix™-Bbiological

Intramuscular, single dose